While it no longer generates the sales it once did, Pfizer's coronavirus lineup remains critical to its results. The past ...

Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553 ...

The NB.1.8.1 variant made up roughly 10.7 per cent of all global infections by late April 2025 – up from just 2.5 per cent ...

A new COVID variant - NB 1.8.1 - is creeping across California; here are the symptoms to watch for, and vaccinations you'll ...

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

The Trump administration is eroding national pandemic flu defenses as it guts health agencies, cuts research and health ...

A new COVID variant has been reported in China, which could lead to another round of COVID booster shots in America.

The US Food and Drug Administration may limit Covid-19 boosters shots to high-risk groups from 2025; Pfizer reviewing proposal as agency seeks new trials, clearer risk labels for younger males ...

Investors reacted favorably to the news and shares of COVID vaccine makers rose. In late morning trading, shares of Moderna were up 11.2% at $29.24, Pfizer rose 2.2% to $23.51 and Novavax shares were ...

Shares of Moderna surged to lead S&P 500 gainers Tuesday after the Food and Drug Administration issued new guidance for COVID ...

There is no “the” vaccine. There are at least two mRNA vaccines (Moderna and Pfizer) and a number of different non-mRNA ...